Rhythm Pharmaceuticals Nachrichten und Aktivitäten
Präsenz
Rhythm Pharmaceuticals ist einer der ...
Rhythm Pharmaceuticals ist ein Unternehmen, das unter dem Börsenticker RYTM (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 19 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Rhythm Pharmaceuticals
- David Meeker, Chairman of Board, President and Chief Executive Off...
- Ed Mathers, Lead Independent Director
- Stuart Arbuckle, Director
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Rhythm Pharmaceuticals nachzuverfolgen.
Pharmazie
Rhythm Pharmaceuticals hat 1.824 Konkurrenten , einschließlich Pfizer (USA), Sanofi (Frankreich) und Roche (Schweiz).
Popular M&A news in Pharmazie
- Cyclo Therapeutics hat Rafael Holdings erworben (veröffentlicht am 28, April 2025).
- Chimerix and Chimerix have merged (veröffentlicht am 22, April 2025)..
- Imbria Pharmaceuticals hat gerade eine Spendenaktion von 58 Millionen Dollar angekündigt. (veröffentlicht am 10, April 2025).
Andere vorgeschlagene Kontakte der Pharmazie branche
Nachrichten
Neueste Pressemitteilungen nach Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals to Present at Investor Conferences in September | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities | Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers | Rhythm Pharmaceuticals, Inc.
- View more press releases Close
Social media about Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals auf Wikipedia, Google News & Yahoo Finance
- Rhythm Pharmaceuticals auf LinkedIn, Twitter & YouTube
